[Screening technologies to advance rapid testing for cervical cancer prevention in developing countries]

Area of Science:

• Oncology
• Virology
• Public Health

Background:

• Cervical cancer remains a significant global health burden, particularly in low- and middle-income countries.
• Existing screening methods have limitations in accessibility, cost, or accuracy in resource-limited settings.
• Human Papillomavirus (HPV) is the primary cause of cervical cancer.

Purpose of the Study:

• To introduce and evaluate the careHPV assay, a novel HPV DNA detection technique for cervical cancer prevention.
• To assess the accuracy and feasibility of careHPV assay in comparison to established methods.
• To highlight the potential impact of careHPV assay on cervical cancer prevention strategies in developing countries.

Main Methods:

• The careHPV assay, developed by the Cancer Hospital, Chinese Academy of Medical Sciences, was utilized for HPV DNA detection.
• Clinical outcomes were used as the endpoint for verifying the testing technique.
• Accuracy was compared against the current standard HPV detection technique and Visual Inspection with Acetic Acid (VIA).

Main Results:

• The careHPV assay is the first HPV DNA detection technique globally that is simple, fast, accurate, safe, and inexpensive.
• Its accuracy was found to be comparable to the standard HPV detection technique.
• The careHPV assay demonstrated higher accuracy than VIA.

Conclusions:

• The careHPV assay represents a significant advancement in cervical cancer screening technology.
• Its widespread adoption could substantially contribute to cervical cancer prevention efforts in China and other developing nations.
• Implementing careHPV assay has the potential to reduce disparities in cervical cancer prevention and decrease disease incidence and mortality globally.